vs
FrontView REIT, Inc.（FVR）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
FrontView REIT, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.8倍（$16.5M vs $9.1M），FrontView REIT, Inc.净利率更高（-24.9% vs -60.3%，领先35.5%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
FVR vs PLX — 直观对比
营收规模更大
FVR
是对方的1.8倍
$9.1M
净利率更高
FVR
高出35.5%
-60.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $9.1M |
| 净利润 | $-4.1M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | — | -51.1% |
| 净利率 | -24.9% | -60.3% |
| 营收同比 | — | -49.9% |
| 净利润同比 | — | -184.8% |
| 每股收益（稀释后） | $-0.19 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRPLX
| Q4 25 | $16.5M | $9.1M | ||
| Q3 25 | $16.8M | $17.9M | ||
| Q2 25 | $17.6M | $15.7M | ||
| Q1 25 | $16.2M | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $14.5M | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q4 23 | — | $10.5M |
净利润FVRPLX
| Q4 25 | $-4.1M | $-5.5M | ||
| Q3 25 | $4.0M | $2.4M | ||
| Q2 25 | $-2.9M | $164.0K | ||
| Q1 25 | $-833.0K | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $-2.4M | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q4 23 | — | $-6.0M |
毛利率FVRPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
营业利润率FVRPLX
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q4 23 | — | -53.5% |
净利率FVRPLX
| Q4 25 | -24.9% | -60.3% | ||
| Q3 25 | 23.9% | 13.2% | ||
| Q2 25 | -16.5% | 1.0% | ||
| Q1 25 | -5.1% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | -16.7% | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q4 23 | — | -57.6% |
每股收益（稀释后）FVRPLX
| Q4 25 | $-0.19 | $-0.06 | ||
| Q3 25 | $0.19 | $0.03 | ||
| Q2 25 | $-0.16 | $0.00 | ||
| Q1 25 | $-0.06 | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q4 23 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.5M | $14.7M |
| 总债务越低越好 | $314.3M | — |
| 股东权益账面价值 | $391.2M | $48.2M |
| 总资产 | $854.4M | $82.3M |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资FVRPLX
| Q4 25 | $13.5M | $14.7M | ||
| Q3 25 | $19.6M | $13.6M | ||
| Q2 25 | $8.4M | $17.9M | ||
| Q1 25 | $3.3M | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q4 23 | — | $23.6M |
总债务FVRPLX
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
股东权益FVRPLX
| Q4 25 | $391.2M | $48.2M | ||
| Q3 25 | $385.2M | $52.9M | ||
| Q2 25 | $369.9M | $49.9M | ||
| Q1 25 | $324.7M | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | $1.0K | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q4 23 | — | $33.6M |
总资产FVRPLX
| Q4 25 | $854.4M | $82.3M | ||
| Q3 25 | $846.8M | $82.3M | ||
| Q2 25 | $856.5M | $78.5M | ||
| Q1 25 | $860.8M | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | $1.0K | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q4 23 | — | $84.4M |
负债/权益比FVRPLX
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $42.1M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流FVRPLX
| Q4 25 | $42.1M | $2.0M | ||
| Q3 25 | $8.3M | $-3.7M | ||
| Q2 25 | $9.3M | $-5.2M | ||
| Q1 25 | $8.1M | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q4 23 | — | $3.6M |
自由现金流FVRPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q4 23 | — | $3.3M |
自由现金流率FVRPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q4 23 | — | 31.9% |
资本支出强度FVRPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | — | 2.4% |
现金转化率FVRPLX
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVR
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
